Ghost Tree Capital’s Aclaris Therapeutics ACRS Stock Holding History

Ghost Tree Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-425,000	Closed	-$3.44M	–	58
2023 Q1	$3.44M	Buy	+425,000	New	+$5.39M	1.02%	34
2022 Q2	–	Sell	-125,000	Closed	-$2.15M	–	34
2022 Q1	$2.15M	Sell	125,000 -200,000	-62%	-$2.73M	0.47%	31
2021 Q4	$4.73M	Buy	325,000 +50,000	+18%	+$758K	1.69%	22
2021 Q3	$4.95M	Buy	275,000 +25,000	+10%	+$401K	1.45%	24
2021 Q2	$4.39M	Sell	250,000 -350,000	-58%	-$7.95M	1.21%	31
2021 Q1	$15.1M	Sell	600,000 -50,000	-8%	-$978K	3.55%	10
2020 Q4	$4.21M	Buy	+650,000	New	+$2.74M	0.94%	30
2017 Q1	–	Sell	-120,000	Closed	-$3.26M	–	68
2016 Q4	$3.26M	Sell	120,000 -55,000	-31%	-$1.4M	0.78%	47
2016 Q3	$4.48M	Buy	+175,000	New	+$3.71M	0.73%	47

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ghost Tree Capital's ACRS Position: Q2 2023 in Review

Ghost Tree Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 425,000 shares — an estimated $3.44M sold.

Ghost Tree Capital first reported a position in ACRS in Q3 2016 and held it in 9 quarters. The position peaked at $15.1M in Q1 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

Ghost Tree Capital reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
Ghost Tree Capital sold 425,000 Aclaris Therapeutics shares in Q2 2023, an estimated $3.44M.
Ghost Tree Capital first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 9 quarters.
Ghost Tree Capital's Aclaris Therapeutics position peaked at $15.1M in Q1 2021.
133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.